New Discoveries in Protein Methylation

A ground-breaking report from scientists at Glaxo and Epizyme has now revealed that the PRMT1 inhibitor, GSK3368715, exhibits potent anti-tumor activity. Extensive chemical and cellular studies support the usefulness of the new chemical compound as a First-In-Class therapeutic agent. Also described in the report are experiments that implicate the endogenous metabolic inhibitor, methyl-thioadenosine (MTA), in … Read more

Research Review Series (2 of 3)

THE INTERSECTION OF CANCER AND PROTEIN METHYLATION   William Pratt, CH3 Biosystems Lab Intern Introduction   Protein arginine methyltransferases (PRMTs) are transcriptional coactivators, a type of coregulator that affects a transcription factor to increase the rate of transcription of a gene by recruiting general transcription machinery to the promoter region. The aberrant expression of PRMTs … Read more

Research Spotlight

Methyltransferase Inhibitors Recent exciting news in the field of personalized medicine of cancer patients: new developments on the collaboration between Epizyme and GlaxoSmithKline may contribute the advancement of cancer treatment research tremendously.  Additionally, there has been new progress made by CH3 BioSystems to create a new drug discovery platform. New development on the collaboration between … Read more

Product Spotlight

Cell Lines Cell lines are derived from normal or diseased tissue that is disaggregated and subjected to limited dilution to generate one or a few cells. Therefore, after several dozen rounds of division, cultures of cell line consist of cells with uniform genetic make-up and additionally homogenous biochemical composition. Here at CH3 BioSystems, our cell lines are … Read more

Arginine methylation of RUNX1 affects peripheral CD4+ T cells in intact mice

Arginine methylation of RUNX1 affects peripheral CD4+ T cells in intact mice RUNX1 (previously termed AML1) is a frequent target of human leukaemia-associated gene aberrations, and it encodes the DNA-binding subunit of the Core-Binding Factor transcription factor complex. RUNX1 expression is essential for the initiation of definitive haematopoiesis, for steady-state thrombopoiesis, and for normal lymphocytes … Read more